Sanofi American Depository Receipts (ADR) represents a division of Sanofi S.A, an international pharmaceutical corporation based in France, that trades on U.S securities exchanges. Translated as 'healthy life in Latin', Sanofi is a global giant in the healthcare industry, famous for its mainstay drug products, vaccines, and innovative therapies.
Sanofi S.A was founded in 1973 following a merger between other French companies. Since its birth, the company has expanded its footprint globally, making it one of the world’s leading biopharmaceutical organizations, with a presence in over 100 countries. The company's commitment to research, development, and innovation has positioned it as a pioneer in healthcare.
Sanofi ADR (SNY) works to sell and distribute Sanofi products in the United States. Its shares are traded just like other U.S equity securities on major stock exchanges such as the New York Stock Exchange (NYSE). This makes the organization's shares accessible to a broad array of investors.
The company’s portfolio is remarkably diverse, covering various therapeutic areas including diabetes, cardiovascular diseases, rare diseases, multiple sclerosis, oncology, and immunology. These advancements have been powered by a keen focus on research and development, where the organization dedicated over €5 billion in 2019 alone. Sanofi also has a rich history in vaccine development through the Sanofi Pasteur branch, the largest company globally solely dedicated to vaccines.
Sanofi ADR's business strategy encompasses mergers and acquisitions to bring innovative therapies to patients more quickly. An example is its acquisition of Genzyme Corporation in 2011, a biotechnology company that has significantly helped Sanofi to expand its footprint in rare disease and multiple sclerosis markets.
Besides, it's notable to mention its efforts in managing the COVID-19 global pandemic, with Sanofi and GSK partnering to develop a COVID-19 vaccine. This showcases the company's commitment to global health.
Overall, the organization's primary motivation is to be a trusted partner for a healthier world. Its major ambitions include harnessing breakthrough scientific advances, targeting significant unmet patient needs and placing the patient at the heart of everything they do.
Sanofi ADR's contributions to the healthcare sector, its commitment to innovation, and its agility in responding to global health crises, further reaffirming their position as a leader in healthcare. However, like all investments, its stock comes with potential risks and rewards, and investors are therefore advised to carefully analyse and consider these factors before investing.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Sanofi's stock has reached a 250-session high, climbing 1.75% and becoming a top performer on the CAC 40 index. This surge extends its strong October rebound, driven by the pharmaceutical group raising its 2026 targets after the third quarter. The stock is currently trading at €88.15, well above its 200-day moving average, though its RSI indicates an overbought condition.
Sanofi's shares have gained momentum following the commencement of Phase 3 trials for its influenza COVID-19 combination vaccine, which could lead to significant commercialization. While a community-based valuation model suggests the stock is almost 20% overvalued at €86.61 compared to a fair value of €72.23, a discounted cash flow (DCF) model indicates it is heavily undervalued at €268.02 per share. Investors are left to weigh these differing valuation perspectives alongside the potential success of the vaccine and patent pressures.
Windward Bio is pursuing a $204 million IPO to advance its respiratory drug pipeline, primarily focusing on two candidates licensed from China. The Swiss biotech plans to use the proceeds to fund phase 2 and 3 trials for WIN378, an anti-TSLP antibody for COPD and asthma, and a phase 2b study for WIN027, a dual TSLP and IL-13 inhibitor for COPD and atopic dermatitis. Sanofi's venture arm, already an investor, has also agreed to a $50 million private placement alongside the IPO.
BNP Paribas Exane has upgraded Sanofi (SNY) from Neutral to Outperform, a move expected to positively influence trader sentiment. The report provides historical context on SNY's stock performance following previous headlines and explains what an analyst upgrade entails. Quantisnow, a real-time market data platform, delivered this alert to its Plus members.
Nurix Therapeutics experienced a significant stock decline after Sanofi terminated the development of SAR448272, a Phase I immunology candidate, despite a recent milestone payment. While Sanofi cited nonclinical findings as the reason, analysts speculate that broader portfolio strategies or data from other collaborations might have influenced the decision. Nurix maintains a strong financial position due to its collaboration with Roche on bexobrutideg, a BTK degrader with a large addressable market opportunity.
Shares of Nurix Therapeutics (NRIX) fell 38% after Sanofi discontinued the development of an experimental oral drug, SAR448272, that it had licensed from Nurix. Wells Fargo subsequently lowered its price target on Nurix to $20 from $25, maintaining an Equal Weight rating, citing the loss of an asset to which it had attributed $400 million in value and the elimination of potential milestone payments. Despite the setback, Nurix maintains a strong cash position expected to fund operations into the second half of 2029.
Sanofi has launched an "emotive" RSV campaign to raise awareness of bronchiolitis, a potential complication of RSV in young children. The campaign features a PSA video where parents listen to sounds of a baby struggling to breathe and are asked what the sound means to them. Sanofi, alongside AstraZeneca, markets Beyfortus, a drug designed to prevent RSV from progressing to bronchiolitis, and hopes this awareness push will boost declining sales for the new RSV season.
Sanofi has discontinued its early-stage STAT6 degrader program, licensed from Nurix Therapeutics, causing Nurix's shares to fall by over 30%. Analysts attribute Sanofi's decision to molecule-specific issues with SAR448272 or strategic reprioritization, rather than a broader concern with the STAT6 drug class itself. Despite the setback, Nurix's valuation is largely tied to its collaboration with Roche for the BTK degrader bexobrutideg.
Sanofi has discontinued a STAT6 degrader program (SAR448272) developed with Nurix, only two months after it entered Phase 1 clinical trials for type 2 inflammatory diseases. This decision comes despite a $10 million milestone payment to Nurix upon the trial's launch and is part of a broader pipeline restructuring at Sanofi. Nurix maintains a strong position with other clinical-stage programs and partnerships, including those with Roche and Gilead.